Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2022 | New drugs for the treatment of GvHD

John Murray • 22 Mar 2022
EBMT 2022
General Belumosudil Ibrutinib Ruxolitinib
REACH2

John Murray, RGN, MSc, Christie Hospital NHS Foundation Trust, Manchester, UK, discusses new opportunities for the treatment of graft-versus-host disease (GvHD), with the introduction of new drugs such as ibrutinib and ruxolitinib, which became available following the REACH2 trial (NCT0291326). In addition, belumosudil, another drug for GvHD, has recently been approved by the FDA, with clinical trials also happening in Europe. Depending on the hospital and country, a range of treatments are now available to treat GvHD. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.

More from John Murray

2:38
The vital role of nursing in the diagnosis and management of acute & chronic GvHD
John Murray • 24 Apr 2023
1:49
Top 3 nursing challenges in 2023: staff retention, recruitment & training
John Murray • 24 Apr 2023
1:05
Pros & cons of ambulatory transplant care
John Murray • 22 Mar 2022
0:46
The importance of nurse-doctor communication in transplant patients
John Murray • 22 Mar 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals